Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cipaglucosidase alfa and miglustat for treatment of late-onset Pompe disease (LOPD): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)

Genetics in Medicine Open(2025)10.1016/j.gimo.2025.103444Source: DataRank Database

Cipaglucosidase alfa and miglustat for treatment of late-onset Pompe disease (LOPD): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG) is a research paper published in Genetics in Medicine Open (2025). On theSindex it has a DataRank of 0.165. It has been cited 2 times.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

2 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 1.33)OA: goldTopics (18)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (4)

Allyson Derry,Jennifer L. Cohen ORCID,Irene J. Chang ORCID,Elizabeth K. Baker

Live enrichment

PubMed:40893835 PMC:PMC12398902 OpenAlex:https://openalex.org/W4413601105

Sanofi Genzyme

Bayer HealthCare

FWCI

1.33

Citation Percentile

0.8%

Citation Trend

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.gimo.2025.103444

publisherhttps://doi.org/10.1016/j.gimo.2025.103444

publisherhttps://api.elsevier.com/content/article/PII:S2949774425014839?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2949774425014839?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40893835

Fields of Study

Lysosomal Storage Disorders ResearchGlycogen Storage Diseases and MyoclonusChild Nutrition and Feeding Issues

Keywords

Medical geneticsDiseaseMedicineGenomicsGeneticsGerontologyFamily medicineBiologyInternal medicineGenomeGeneEnzyme Replacement TherapyPompe DiseaseCipaglucosidase Alfa And MiglustatPombiliti And Opfolda

Sustainable Development Goals

SDG 0: Good health and well-being

Cipaglucosidase alfa and miglustat for treatment of late-onset Pompe disease (LOPD): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)

FAIR Checklist

DataRank Breakdown

Authors (4)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)